^{18}F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis—The Central Role of Volume

James C. Reynolds[1], Roberto Maass-Moreno[1], Anish Thomas[2], Alexander Ling[1], Emerson B. Padiernos[3], Seth M. Steinberg[4], and Raffit Hassan[3]

[1]Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland; [2]Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; [3]Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and [4]Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

Cancer survival is related to tumor volume. ^{18}F-FDG PET measurement of tumor volume holds promise but is not yet a clinical tool. Measurements come in 2 forms: the first is total lesion volume (TLV) based on the number of voxels in the tumor, and the second is total lesion glycolysis (TLG), which is the TLV multiplied by the average SUL (i.e., SUV normalized for lean mass) of the tumor ($SUL_{average}$). In this study, we measured tumor volume in patients with malignant pleural mesothelioma (MPM). **Methods:** A threshold-based program in Interactive Data Language was developed to measure tumor volume in ^{18}F-FDG PET images. Nineteen patients with MPM were studied before and after 2 cycles (6 wk) of chemoimmunotherapy. Measurements included TLV, TLG, the sum of the SULs in the tumor (SUL_{total}, a measure of total ^{18}F-FDG uptake), and $SUL_{average}$. **Results:** Baseline TLV ranged from 11 to 2,610 cm^3. TLG ranged from 32 to 8,552 cm^3 g/mL and correlated strongly with TLV. Although tumor volumes ranged over 3 orders of magnitude, $SUL_{average}$ stayed within a narrow range of 2.4–5.3 units. Thus, TLV was the major component of TLG, whereas $SUL_{average}$ was a minor component and was essentially constant. Further evaluation of $SUL_{average}$ showed that in this cohort its 2 components, SUL_{total} and TLV, changed in parallel and were strongly correlated ($r = 0.99$, $P < 0.01$). Thus, whether the tumors were large or small, ^{18}F-FDG uptake as measured by SUL_{total} was proportional to the TLV. **Conclusion:** TLG equals TLV multiplied by $SUL_{average}$, essentially TLV multiplied by a constant. Thus TLG, commonly considered a measure of metabolic activity in tumors, is also in this cohort a measure of tumor volume. The constancy of $SUL_{average}$ is due to the fact that ^{18}F-FDG uptake is proportional to tumor volume. Thus, in this study, ^{18}F-FDG uptake was also a measure of volume.

Key Words: ^{18}F-FDG PET; pleural mesothelioma; TLV; TLG

Malignant pleural mesothelioma (MPM) is an aggressive tumor that often presents as pleural thickening or rind, with involvement of pleural fissures, the chest wall, or the mediastinum (1). A strong indicator of cancer prognosis is the size of tumor, but determining the size of MPM is a major challenge. Because linear measurements are unreliable, a modified RECIST method was developed that measured the thickness of the pleural rind at several levels (2). Another approach is to measure tumor volume directly by CT. New automated CT analysis programs further this effort, but as shown in a pilot study, scan interpreters can have different perceptions of the extent of disease and of separation of the tumor from adjacent normal tissue (3).

Against this background is the use of ^{18}F-FDG PET imaging not only for tumor localization, response to therapy, and recurrence but also as a measure of tumor volume and metabolic activity. Applied to MPM, ^{18}F-FDG PET imaging provides a simple approach for measuring both tumor volume and metabolic activity. One approach is to define an SUL (i.e., SUV normalized for lean mass) threshold above which voxels are counted as the total lesion volume (TLV) (4–7). A second measurement that can be obtained from ^{18}F-FDG PET images is the total lesion metabolic activity, commonly designated total lesion glycolysis (TLG) (8). Previous reports of MPM have shown that TLV, TLG, or both are correlated with overall patient prognosis (5–7,9–11).

For this report, we used a background threshold–based program to analyze ^{18}F-FDG PET images for TLV (4) and TLG. Subjects were patients with MPM who received an antimesothelin immunotoxin with chemotherapy. We explored the relationship of TLV, SUL_{total}, $SUL_{average}$, and TLG. We found that in this cohort, like TLV, TLG was a measurement of tumor volume.

MATERIALS AND METHODS

Patients

Nineteen patients (84% male; median age, 67 y; range, 52–76 y) with histologically confirmed MPM and measurable stage III or IV disease were enrolled in a phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin (12). Pemetrexed and cisplatin were administered every 3 wk for up to 6 cycles, whereas SS1P was administered intravenously on days 1, 3, and 5 every 3 wk for 2 cycles—that is, for only the first 6 wk. For the study, CT and ^{18}F-FDG PET/CT scans were obtained at baseline and

**FIGURE 1.** Tumor nodule volumes on ^{18}F-FDG PET vs. CT. Measurements were performed in duplicate. Inset shows nodules smaller than 40 cm[3].

contemporary CT studies using a PACS CT volume measurement program (16). Nodules were selected because visually they had uniform ^{18}F-FDG activity without evidence of necrosis. The CT volumes ranged from 0.5 to 428 cm[3]. ^{18}F-FDG PET and CT measurements were nearly identical; a regression line relating the two had a slope of 0.982 and a y intercept of 0.4 (Fig. 1). The percentage coefficient of variation of duplicate analyses of nodule volumes was 1.2%, and the 95% confidence interval was 3.3% (14,15).

Measurements and Calculations. The Interactive Data Language program made 2 measurements. It first determined the number of voxels with SULs equal to or greater than the threshold. Multiplying this value by the volume of a single voxel gave the TLV (Fig. 2A). The SULs in these voxels were then summed to give the total SUL in the tumor (SUL$_{total}$) (Fig. 2B). Because SUL$_{total}$ is affected by voxel size, SUL$_{total}$ was corrected to represent 16.9 voxels/cm[3], the largest voxel size encountered in this study.

every 6 wk. Thoracic CT scans were analyzed by measuring tumor thickness at the chest wall and mediastinum at 3 levels, according to the modified RECIST procedure (2). Only the baseline and 6-wk results were used for this report. The study protocol was approved by the Institutional Review Board of the National Cancer Institute, National Institutes of Health, and all patients gave written informed consent in accordance with the National Cancer Institute Institutional Review Board regulations.

^{18}F-FDG PET/CT Studies

Patients fasted 4–6 h before undergoing ^{18}F-FDG PET/CT imaging, had fasting blood glucose values of less than 200 mg/dL, and were studied about 1 h after administration of an average dose of 556 MBq of ^{18}F-FDG. Images were acquired with either a Siemens Biograph 128 or a GE Healthcare Discovery ST and were processed using iterative reconstruction (3 iterations, 21 or 22 subsets) with point-spread function correction or both point-spread function and time-of-flight corrections. ^{18}F-FDG PET/CT volume measurements were considered exploratory and not used for treatment decisions.

^{18}F-FDG PET/CT Image Analysis

^{18}F-FDG PET measurements were expressed as SUL. A background threshold–based program written in Interactive Data Language (version 8.0) quantified the tumor volume and overall ^{18}F-FDG activity. The threshold was determined by measuring the average SUL activity within a 3-cm-diameter sphere in the liver and then multiplying this value by 1.5 and adding twice the SEM of the voxels within the sphere (13) (mean liver SUL at baseline and 6 wk was 1.81 ± 0.04 and 1.80 ± 0.04, respectively; $P = 0.15$). This procedure created a mask of positive voxels, which was further edited to exclude nontumor tissue (e.g., brain, heart, and kidney) and compared with ^{18}F-FDG PET images to ensure that all tumor was included. Thirty-eight ^{18}F-FDG PET studies were analyzed in duplicate; their mean values are reported here. The percentage coefficient of variation of duplicate analyses of TLV was 2.5%, and the 95% confidence interval was 7.0% (14,15).

To validate the accuracy of the Interactive Data Language program, we assessed 35 malignant nodules (including renal, adrenal, mesothelioma, and lymphoma, approved National Institutes of Health ^{18}F-FDG PET scans; patients were deceased at the time of the current analysis so that under title 45 *Code of Federal Regulations,* part 46, institutional review board approval or an exemption for this research was unneeded), comparing the ^{18}F-FDG PET volumes with those in


FIGURE 2. The 19 patients at baseline and 6 wk: TLV (A), SUL$_{total}$ (B), SUL$_{average}$ (C), and TLG (D). Order is based on volume at baseline and 6 wk.

Parameter	TLG	$SUL_{average}$	SUL_{total}
Baseline TLV	0.99 ($P < 0.01$)	0.20 ($P = 0.41$)	0.99 ($P < 0.01$)
6 wk TLV	0.99 ($P < 0.01$)	0.10 ($P = 0.67$)	0.98 ($P < 0.01$)
Therapy response*	0.95 ($P < 0.01$)	−0.29 ($P = 0.23$)	0.93 ($P < 0.01$)

*[Baseline value - 6-wk value]/baseline value.

Two further calculations were made: $SUL_{average}$ was calculated by dividing SUL_{total} by the number of voxels in the tumor (Fig. 2C), and TLG was calculated by multiplying TLV by $SUL_{average}$. (Fig. 2D).

Statistical Methods. The relationship between pairs of measurements, TLV, TLG, $SUL_{average}$, and SUL_{total} was determined using Spearman correlation analysis (Table 1). The results were interpreted as strong correlation, $r > 0.70$; moderately strong correlation, $0.50 < r < 0.70$; or weak correlation, $r < 0.30$. Since P values test at $r = 0$, the most important information is the magnitude of the correlation.

RESULTS

TLV, TLG, and $SUL_{average}$

Baseline TLV ranged from 11 to 2,610 cm^3, and the corresponding TLG ranged from 32 to 8,552 cm^3 g/mL. With 6 wk of therapy, there was a dramatic reduction in both TLV and TLG, with a median response of 75% in each (Supplemental Figs. 1 and 2; supplemental materials are available at http://jnm.snmjournals.org). After 6 wk of therapy, TLV ranged from 0 to 1,460 cm^3 and the corresponding TLG was 0 to 4,470 cm^3 g/mL. Both at baseline and at 6 wk, TLG and TLV were strongly correlated, as were the percentage changes in the two with therapy (Table 1).

As is evident in Figure 2C, there was minimal variation in $SUL_{average}$ despite the wide range of tumor volumes. When compared with TLV, $SUL_{average}$ was a relatively minor contributor of TLG, ranging from 2.4 to 5.3 and averaging the same before and after therapy (3.64 ± 0.16 at baseline vs. 3.61 ± 0.16 at 6 wk, $P = 0.87$) (Fig. 3). Thus, as in Figure 4A, a side-by-side comparison of TLG and TLV, and in Figure 4B, showing the changes in the 2 measurements with therapy, TLG was essentially determined by TLV. The dominance of TLV in TLG is also evident in


FIGURE 3. $SUL_{average}$ at baseline and 6 wk.

plots of survival versus TLV and TLG (Figs. 5A and 5B). Except for the shift to the right in the TLG figure, the 2 curves appear very similar.

SUL_{total} and TLV

Since voxel number equals TLV divided by the volume of a single voxel, the $SUL_{average}$ formula can be written as {SUL_{total}/TLV} multiplied by the single voxel volume. The reason that $SUL_{average}$ was relatively constant was that the ratio of SUL_{total} to tumor volume was relatively constant. As shown in Figure 6, SUL_{total} is linearly related to tumor volume. SUL_{total} also strongly correlates with TLV (Table 1). Since SUL_{total} is an expression of total ^{18}F-FDG uptake, the relationship of SUL_{total} to tumor volume also means that the ^{18}F-FDG uptake by these tumors is essentially proportional to the volume. Side-by-side comparison of SUL_{total} and TLV (Fig. 7A), as well as the changes in the 2 measurements with therapy (Fig. 7B), shows that as these tumors enlarged or responded to therapy, ^{18}F-FDG uptake per tumor volume remained constant.

DISCUSSION

Important for this study was to show that the ^{18}F-FDG-volume program was both accurate and reproducible and that the measurements were consistent with visual interpretation of MPM ^{18}F-FDG PET scans before and after therapy (Supplemental Fig. 1). ^{18}F-FDG PET measurement of TLV was also correlated with modified RECIST measurements at baseline ($r = 0.72$, $P < 0.01$) and at 6 wk ($r = 0.63$, $P < 0.01$). Similar to other reports (5,6,10,11), Kaplan–Meier analysis of baseline ^{18}F-FDG tumor volumes was also an indicator of patient survival (Supplemental Fig. 3). Perhaps more important was that the relationship of baseline ^{18}F-FDG PET volume to survival (Fig. 5A) was similar to results in earlier reports that used CT to measure volume. Pass et al., in a groundbreaking report, showed that MPM volumes of less than 100 cm^3 were associated with a median survival of 22 mo, compared with 9 mo for larger tumors (17). A more recent multicenter study also showed favorable survival for tumors smaller than 100 cm^3 and short survival for tumors larger than 500 cm^3 (18).

The similarity of the plots of survival versus TLV and TLG (Figs. 5A and 5B) led to the analysis of $SUL_{average}$, the second component of TLG. A surprising finding was that although tumor volumes varied greatly, $SUL_{average}$ was not dependent on tumor size; it always resided within a narrow range, and its 2 components, SUL_{total} and TLV, were strongly correlated and linearly related. It is unknown whether the constancy of $SUL_{average}$ is a peculiarity of mesothelioma or a more universal characteristic of tumors. However, it appears that as MPM tumors enlarge, the uptake of ^{18}F-FDG increases but in proportion to the change in

FIGURE 4. The 19 patients sorted by TLV and TLG: baseline values (A) and response to therapy (B).

in this instance the measured change in TLG was due to the loss of tumor volume.

In the original article describing TLG, $SUV_{average}$ (SUV body weight average) "was computed by placing a region of interest within the perimeter of the tumor region containing...the SUVmaximum" (8). Thus, like SUV_{max}, $SUV_{average}$ was a local value and, also like SUV_{max}, could change with therapy. $SUV_{average}$ was therefore included as a response variable in the 1999 European Organisation for Research and Treatment of Cancer ^{18}F-FDG PET recommendations (21). The $SUL_{average}$ described in this current report, however, is a global measurement representative of the entire tumor. Although the original definition of TLG has been carried forward (22), it is now recognized that there is a second form of the measurement based on total volume of tumor, for which $SUV_{average}$ is calculated from the entire volume (23). In our studies, we found that $SUL_{average}$ has 2 characteristics. The first is that it is relatively constant for a wide range of tumor sizes. Second, we found that $SUL_{average}$ was not related to overall survival (Supplemental Fig. 4). This finding is consistent with an earlier report of Veit-Haibach et al., who found that the change in $SUV_{average}$ after therapy was not predictive of patient outcome (6). In studies in which the entire volume of MPM tumor was measured using ^{18}F-FDG PET images, $SUV_{average}$ was in the same range as our $SUL_{average}$ results. Using an ^{18}F-FDG PET global volume-of-interest program Veit-Haibach et al. studied total tumor volume, TLG, and $SUV_{average}$ in 41 MPM patients (6). $SUV_{average}$ varied from 2.5 to 6.4 for PET-measured volumes of 2.5–1,799 cm^3 (6). In another study, of 13 patients with MPM, Lee found that $SUV_{average}$ ranged from 2.9 to 6.1 for PET volumes of 14.1–3,056 cm^3 (5). In 8 MPM patients, Genestreti et al. found that $SUV_{average}$ ranged from 1.91 to 3.36 and was not significantly different before and after therapy (24).

The use of regional $SUV_{average}$ to calculate TLG, or the emphasis on finding clinically relevant measurements, could have led investigators away from noticing the relative constancy of $SUV_{average}$ and the finding that in MPM, SUL_{total} was proportional to TLV—specifically, metabolic tumor volume. In the current study, the constant proportionality of SUL_{total} to TLV over a wide range of tumor sizes suggests that the average ^{18}F-FDG uptake per cell is constant despite differences in volume. The relationship of ^{18}F-FDG uptake to cell number was previously shown by histopathologic analyses. In tumors taken from patients who had ^{18}F-FDG PET scans, the ^{18}F-FDG uptake correlated with the number of tumor cells, their density in tissue, and their mitotic activity (20,25,26). ^{18}F-FDG uptake as a measure of cell number may also apply to studies in which the total metabolic activity in tumors is measured. In 1993, Alavi et al. originated the concept of total metabolic activity, a value obtained by multiplying total volume

size. Additionally, the consistent relationship of ^{18}F-FDG uptake to tumor volume was still evident after 2 cycles of therapy that led to dramatic reductions in tumor volume. An assumption about cancers is that as they grow, there is an increase in metabolic activity and ^{18}F-FDG uptake per cell related to increases in Glut-1 transport and hexokinase (19,20). But that does not seem to be the case with MPM, for which the volume and ^{18}F-FDG uptake maintain a constant ratio.

TLG was first defined by Larson et al. as a measure that could be used to assess tumor response to therapy (8). The idea was that the change in metabolic activity (TLG) was a measure of cell killing. TLG is clearly a surrogate for total metabolic activity, but because of the constancy of $SUL_{average}$, TLG in the context of MPM also reflects a volume. The fact that TLG reflects a volume may also explain why patient survival is related to TLG, because cancer survival is related to tumor volume. Therapy led to concordant responses by TLG and TLV (Fig. 4B). Again, because of the constancy of $SUL_{average}$, the relationship between TLG and TLV is one of cause and effect: a change in TLV leads to a change in TLG. Thus, as described by Larson et al., a reduction in TLG, an indicator of tumor metabolism, is a measure of cell killing, but

FIGURE 5. Association curves for survival vs. TLV (A) and survival vs. TLG (B). Solid line indicates inverse function. In A, survival = 3,000/TLV +2.5; in B, survival = 10,000/TLV +2.5.

by ^{18}F-FDG uptake per 100 cm^3 of tissue (*27*). Recently, the concept of global tumor glycolysis (the sum of TLGs to describe the entire disease burden in patients with multiple tumors) has received more interest as a robust response indicator that can be used clinically in an ongoing fashion (*28,29*).


FIGURE 6. Linear plot of SUL$_{total}$ vs. TLV at baseline and 6 wk. Linear regression includes all data. SUL$_{total}$ = 61.18 × (TLV) + 326. r^2 = 0.9575. $P < 0.0001$.


FIGURE 7. The 19 patients sorted by TLV and SUL$_{total}$: baseline values (A) and response to therapy (B).

There are potential limitations to this study. First, the data were obtained from a single study involving a small number of patients. However, other reports of MPM, in which SUV$_{mean}$ was similar to ours, help to validate our findings. Second, MPM is spread over surfaces rather than being a localized tumor mass. Whether this distribution contributes to the specific results is unknown, but certainly, the findings should be tested for other cancers. Third, tumor types with higher metabolic activity may behave quite differently. Last, our method for determining TLV from ^{18}F-FDG PET scans is a background-threshold approach in which liver was used as the background tissue (*4*). Our method for determining the threshold was patterned after PERCIST version 1, except that instead of setting the threshold as the average liver activity multiplied by 1.5 plus 2 SDs, we replaced SD with 2 SEs (*13*). This choice lowered our threshold so that small lesions visible in the ^{18}F-FDG PET scans were included in the measured volume. With this threshold, the segmented MPM volume was, imagewise, consistent with the visible extent of disease.

CONCLUSION

Tumor volume is an important biomarker of survival. ^{18}F-FDG PET measurements expressed as TLV or TLG—often considered a measure of metabolic activity—strongly correlate with each other, and both are measures of volume. In this study of MPM, there was a cause-and-effect relationship between tumor volume and TLG. This study also showed that total ^{18}F-FDG uptake, measured as SUL$_{total}$, was always proportional to TLV even when tumors varied greatly in size or after response to therapy. This finding was totally unexpected, since standard teaching suggests that changes in metabolism as measured by ^{18}F-FDG uptake precede changes in

volume. MPM may be a special case in which ^{18}F-FDG uptake per cell and cell proliferation change together. To an extent, our results are a reflection of measuring the entire visible tumor. The relationship between ^{18}F-FDG uptake and total metabolic tumor volume is a global characteristic that may not reflect regional variations, such as in areas that include SUV_{max} and SUV_{peak}. This study showed that TLG and ^{18}F-FDG uptake in MPM were measurements that reflected the tumors' total metabolic volume. Whether these results will be obtained for other tumors needs further study.

DISCLOSURE

ACKNOWLEDGMENT

KEY POINTS

QUESTION: Is ^{18}F-FDG tumor uptake a measure of metabolism or of tumor volume?

PERTINENT FINDINGS: In a cohort of MPM patients studied with ^{18}F-FDG PET, the average SUL concentration per voxel was essentially constant, at a range of 2.4–5.3, despite a tumor size that varied from 1 to 2,610 cm³. This finding indicates that TLG was a volume measurement. The reason that $SUL_{average}$ per voxel was relatively constant was that ^{18}F-FDG uptake by these tumors was proportional to their volume, indicating that ^{18}F-FDG uptake itself was a measure of tumor volume.

IMPLICATION FOR PATIENT CARE: ^{18}F-FDG tumor uptake, commonly considered a measure of tumor metabolism, is also a measure of tumor volume, a finding that applies to MPM and probably other tumors as well.

REFERENCES

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. *N Engl J Med.* 2005;353:1591–1603.
2. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. *Ann Oncol.* 2004;15:257–260.
3. Gill RR, Naidich DP, Mitchell A, et al. North American multicenter volumetric CT study for clinical staging of malignant pleural mesothelioma: feasibility and logistics of setting up a quantitative imaging study. *J Thorac Oncol.* 2016;11:1335–1344.
4. Im HJ, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? *Nucl Med Mol Imaging.* 2018;52:5–15.
5. Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of ^{18}F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. *Ann Surg Oncol.* 2010;17:2787–2794.
6. Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. *Lung Cancer.* 2010;67:311–317.
7. Francis RJ, Byrne MJ, van der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial ^{18}F-FDG PET scans. *J Nucl Med.* 2007;48:1449–1458.
8. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. *Clin Positron Imaging.* 1999;2:159–171.
9. Lopci E, Zucali PA, Ceresoli GL, et al. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. *Eur J Nucl Med Mol Imaging.* 2015;42:667–675.
10. Kitajima K, Doi H, Kuribayashi K, et al. Prognostic value of pretreatment volume-based quantitative ^{18}F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. *Eur J Radiol.* 2017;86:176–183.
11. Klabatsa A, Chicklore S, Barrington SF, Goh V, Lang-Lazdunski L, Cook GJ. The association of ^{18}F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. *Eur J Nucl Med Mol Imaging.* 2014;41:276–282.
12. Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. *Cancer.* 2014;120:3311–3319.
13. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. *J Nucl Med.* 2009;50(suppl 1):122S–150S.
14. Bonnick SL, Johnston CC, Jr, Kleerekoper M, et al. Importance of precision in bone density measurements. *J Clin Densitom.* 2001;4:105–110.
15. Glüer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. *Osteoporos Int.* 1995;5:262–270.
16. Folio LR, Sandouk A, Huang J, Solomon JM, Apolo AB. Consistency and efficiency of CT analysis of metastatic disease: semiautomated lesion management application within a PACS. *AJR.* 2013;201:618–625.
17. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. *J Thorac Cardiovasc Surg.* 1998;115:310–317.
18. Rusch VW, Gill R, Mitchell A, et al. A multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma. *Ann Thorac Surg.* 2016;102:1059–1066.
19. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. *J Nucl Med.* 1996;37:1042–1047.
20. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of [18]fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. *J Clin Oncol.* 2002;20:379–387.
21. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [^{18}F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. *Eur J Cancer.* 1999;35:1773–1782.
22. Sarikaya I, Sarikaya A. Assessing PET parameters in oncologic ^{18}F-FDG studies. *J Nucl Med Technol.* December 6, 2019 [Epub ahead of print].
23. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging—version 2.0. *Eur J Nucl Med Mol Imaging.* 2015;42:328–354.
24. Genestreti G, Moretti A, Piciucchi S, et al. FDG PET/CT response evaluation in malignant pleural mesothelioma patients treated with talc pleurodesis and chemotherapy. *J Cancer.* 2012;3:241–245.
25. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. *J Nucl Med.* 1998;39:1727–1735.
26. Brücher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. *Ann Surg.* 2001;233:300–309.
27. Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. *J Nucl Med.* 1993;34:1681–1687.
28. Høilund-Carlsen PF, Edenbrandt L, Alavi A. Global disease score (GDS) is the name of the game! *Eur J Nucl Med Mol Imaging.* 2019;46:1768–1772.
29. Marin-Oyaga VA, Salavati A, Houshmand S, et al. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature. *Hell J Nucl Med.* 2015;18:11–18.